Reata Pharmaceuticals Sets IPO Pricing Range

Irving, Texas-based pharamceuticals developer Reata Pharmaceuticals has set the estimated pricing range for its IPO, saying that it expects to offer up 4,000,000 shares of its common stock at between $14.00 and $16.00 per share. The company has applied to list on the NASDAQ Global Market as RETA. The IPO is being underwritten by Citigroup, Cowen and Company, and Piper Jaffray. Reata is backed by CPMG, Novo A/S, Cardinal Investment Company, and AbbVie, among others.